At week 12 , PASI75 responses were recorded in 130 ( 395 % ) of 329 patients in the tofacitinib 5 mg group , 210 ( 636 % ) of 330 in the tofacitinib 10 mg group , 197 ( 588 % ) of 335 in the etanercept group , and six ( 56 % ) of 107 in the placebo group .